Lipitor
Lipitor did not just have a great positioning, "Lower is better". It had a market-shaping programme that made that positioning inevitable.
- $150Blifetime revenue
- $12.9Bpeak sales, 2006
- 50%+market share
- 4Mcardiovascular events averted
Prime the Paradigm
NCEP targets moved from below 130 mg/dL to below 100 mg/dL. Patients who were "controlled" became "inadequately controlled", and the drug that could get them to the new target was Lipitor.
Opinion leaders and stakeholder narratives
86,000 primary care physicians reached through symposia. The KOLs were not selling a drug; they were selling a new standard, translated for the physician, the payer and the patient.
Therapeutic gaps and guidelines
Population data laid over the new target showed exactly how many "controlled" patients now fell short, turning a guideline change into a quantified, urgent gap.
Innovation incentives and evidence
The FDA accepted LDL as a surrogate endpoint, saving an estimated $300 million and two to three years of development.
Nurture Network Effects
Physician communities and heart-health advocates folded "lower is better" into their own teaching and campaigns. The paradigm, once shifted, kept shifting on its own.
The drug was well positioned. The market was well shaped.